Brean Capital reaffirmed their buy rating on shares of Cardiome Pharma Corp (NASDAQ:CRME) in a research report released on Thursday morning, Market Beat Ratings reports. Brean Capital currently has a $13.00 …
Mideast Times · 10/7/2015
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Cardiome Pharma Corp (CRME) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands …
The Street · 10/1/2015
Oversold Conditions
Cardiome Pharma Corp (NASDAQ:CRME) was up 4.9% during trading on Friday , Analyst Ratings reports. The company traded as high as $8.53 and last traded at $8.53, with a volume of 436,499 shares …
Ticker Report · 10/10/2015
More from Bing News
Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”). Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative ...
Investor Place · 10/2/2015
Pharmaceutical Stocks
Shares of Cardiome Pharma Corp (NASDAQ:CRME) have received a consensus recommendation of “Buy” from the seven analysts that are currently covering the firm, AnalystRatings.Net reports. One investment analyst has rated the stock with a sell ... · 10/2/2015
However, such confirmation must not delay the start of treatment. Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at
Financial Content · 9/30/2015
Promotion Agreement
Cardiome Pharma Corp (NASDAQ:CRME) fell 2% during trading on Monday , MarketBeat Ratings reports. The company traded as low as $7.68 and last traded at $7.95, with a volume of 52,195 shares changing hands. The stock had previously closed at $8.11. · 10/6/2015
Click to get this free report CARDIOME PHARMA (CRME): Free Stock Analysis Report ARATANA THERAP (PETX): Free Stock Analysis Report To read this article on click here. Zacks Investment Research
Yahoo Finance · 1/15/2015
Cardiome Pharma Corp. ( CRME) was a big mover last session with its shares rising over 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company …
NASDAQ · 6/23/2014
Since the position has been revealed the stock has gained over 40%. Analysts at Canaccord Genuity upgraded shares of Cardiome Pharma Corp (NASDAQ:CRME) to a buy rating from its previous hold rating. R.F Lafferty started coverage on the stock with …
INSIDER MONKEY · 3/14/2014